Time filter

Source Type

Mokarram P.,Gastroenterohepatology Research Center | Kavousipour S.,Gastroenterohepatology Research Center | Sarabi M.M.,Gastroenterohepatology Research Center | Mehrabani G.,Gastroenterohepatology Research Center | And 4 more authors.
Asian Pacific Journal of Cancer Prevention | Year: 2015

Inflammatory bowel disease (IBD) is a disease strongly associated with colorectal cancer (CRC) as a well-known precancerous condition. Alterations in DNA methylation and mutation in K-ras are believed to play an early etiopathogenic role in CRC and may also an initiating event through deregulation of molecular signaling. Epigenetic silencing of APC and SFRP2 in the WNT signaling pathway may also be involved in IBD-CRC. The role of aberrant DNA methylation in precancerous state of colorectal cancer (CRC) is under intensive investigation worldwide. The aim of this study was to investigate the status of promoter methylation of MGMT- B, APC1A and SFRP2 genes, in inflamed and normal colon tissues of patients with IBD compared with control normal tissues. A total of 52 IBD tissues as well as corresponding normal tissues and 30 samples from healthy participants were obtained. We determined promoter methylation status of MGMT-B, SFRP2 and APC1A genes by chemical treatment with sodium bisulfite and subsequent MSP. The most frequently methylated locus was MGMT-B (71%; 34 of 48), followed by SFRP2 (66.6 %; 32 of 48), and APC1A (43.7%; 21 of 48). Our study demonstrated for the first time that hypermethylation of the MGMT-B and the SFRP2 gene promoter regions might be involved in IBD development. Methylation of MGMT-B and SFRP2 in IBD patients may provide a method for early detection of IBD-associated neoplasia.

Mehrabani D.,Stem Cell and Transgenic Technology Research Center | Hosseini S.V.,Laparascopy Research Center | Rezaianzadeh A.,Gastroenterohepatology Research Center | Amini M.,Laparascopy Research Center | And 2 more authors.
Journal of Research in Medical Sciences | Year: 2013

Background: Worldwide, cancer of stomach is still the fourth common cancer and the second cause of mortality among all cancers affecting annually 870, 000 subjects. This study aims to determine the frequency and the characteristics of gastric cancer in southern Iran. Materials and Methods: 10, 800 of all cancers registered in Fars Hospital-based Cancer Registry were surveyed among which 574 cases were gastric cancer in both genders and all age groups. From January 2002 to December 2007, all hospital-based data were recorded according to International Classification of Disease for Oncology (ICD-O) and registered cases included all invasive cancers in ICD-10 categories of C-00 to C-80 and all duplicate cases were eliminated. Results: Among all registered cancers, there were 574 cases of gastric cancer including 69.3% males. The mean age of patients was 58.1 ± 14.8 years, 25.4% with a history of in their first relatives and most of them were smokers (50.9%) and from low socioeconomic class (45.5%). Metastasis was visible in 182 patients and majority of them underwent surgery (64.3%). The majority of gastric cancer patients were older than 50 years, smokers, low socioeconomic class, and female in favor of adenocarcinoma. Conclusion: Our results showed that in our area, treatment programs and health plans should focus on men, patients older than 50 years and with adenocarcinoma, smokers, and those in a low income level.

Dehghani S.M.,Gastroenterohepatology Research Center | Askarian M.,Shiraz University of Medical Sciences | Kaffashan H.A.,Gastroenterohepatology Research Center
Indian Journal of Gastroenterology | Year: 2014

Background: Chronic constipation represents a common problem in children. The treatment of functional constipation is challenging. Some studies have investigated the effect of prokinetic agents as potential therapies for motility disorders of the lower gastrointestinal tract with paradoxical results. The present study aimed to investigate the effect of oral domperidone in the treatment of chronic functional constipation in children. Method: A total of 105 children with chronic functional constipation (according to Rome III criteria) who were referred to the Pediatric Gastroenterology Clinic were recruited in this double-blind randomized clinical trial. The study subjects were randomly divided into two groups, the first of which received polyethylene glycol (PEG) solution 0.6 g/kg/day two times a day for 6 months and domperidone syrup 0.15 mL/kg three times a day for 3 months (case group) while the second one received PEG with the same dose for 6 months and placebo for 3 months with the same dose (control group). The two groups were compared regarding their symptoms and Rome III criteria through 1, 3, and 6 months following therapy. Primary outcome was response to treatment, and a response was defined as decrease in signs and symptoms that did not fulfill Rome III criteria. Secondary outcome measures were side effects during the course of treatment. Results: A significant difference was observed both before and after PEG and domperidone treatment and before and after PEG and placebo treatment regarding Rome III criteria. There was no significant difference in response to treatment between the two study groups during 1 (p = 1), 3 (p = 0.799), and 6 (p = 0.403) month follow up periods. Also, the two groups were not significantly different regarding the Rome III criteria during the mentioned follow up periods. There were no side effects during the course of treatment. Conclusion: There was no additional effect of domperidone as adjunct to PEG in the treatment of children with constipation. © 2013 Indian Society of Gastroenterology.

Amini M.,Shiraz University of Medical Sciences | Kherad M.,Shiraz University of Medical Sciences | Mehrabani D.,Gastroenterohepatology Research Center | Azarpira N.,Shiraz University of Medical Sciences | And 2 more authors.
Journal of Applied Animal Research | Year: 2010

To determine the effect of Plantago major on healing of burn wounds, 100 male Sprague-Dawley 180-220 g rats were randomly divided into 4 groups. Groups of A, B and C each comprised of 30 rats, which were treated with silver sulfadiazine, 20% and 50% Plantago major solution. Group D comprised of 10 rats, which were considered as control group and were treated with Oserin. After 7, 14 and 21 d of treatment, the animals were sacrificed, burn areas were examined histopathologically and scored. There was no significant difference between groups on d 7 and 14 but the difference was significant on d 21. The best results were noticed in group C receiuing 50% P. major solution. So Plantago major may be a suitable substitute for silver sulfadiazine especially when applied in 50% concentration.

Hazrati M.,The College of Nursing and Midwifery | Mehrabani D.,Gastroenterohepatology Research Center | Japoni A.,Alborzi Clinical Microbiology Research Center | Azarpira N.,Transplantation Research Center | And 2 more authors.
Journal of Applied Animal Research | Year: 2010

To determine the effect of honey on healing of burn wounds infected with Pseudomonas aeruginosa, 57 male Sprague-Dawley 180-220 g rats were randomly divided into 3 equal groups (A-C). Group A (control) did not receive any treatment, group B was treated with honey and group C with silver sulfadiazine. After 24 h of burn production, 10 8 colony forming units (CFU) of toxigenic strains of P. aeruginosa (PA 103) were inoculated subcutaneously into the burnt area. Samples were obtained from the infected areas for the presence of P. aeruginosa on the 2 nd, 7 th, 14 th and 21 st d post burns. After 1, 2 and 3 weeks, the animals were sacrificed and burn areas were examined histologically. Bacterial count on the d 2 was 10 5 P. aeruginosa. On d 7, 14 and 21, there was a significant decrease in the number of bacteria in groups B and C. Re-epithelization was significantly more in honey group on d 14 in comparison to silver sulfadiazine and the control. Based on this experiment, application of honey for treatment of burn site even infected with P. aeruoginosa could be safe. However, to clinically use this natural product more supportive trials are needed. © GSP, India.

Discover hidden collaborations